|
Showing 1 - 11 of
11 matches in All Departments
The NATO Advanced Studies Institute series "Targeting of Drugs" was
originated in 1981. It is now a major international forum, held
every two years in Cape Sounion, Greece, in which the present and
the future of this important area of research in drug delivery is
discussed in great depth. Previous ASIs of the series dealt with
drug carriers of natural and synthetic origin, their interactions
with the biological milieu, ways by which milieu interference is
circumvented, approaches to carrier design or modification that
contribute to optimal carrier function, and, more recently, with
strategies for gene and oligonucleotide delivery in therapy The
present book contains the proceedings of the 9th NATO ASI,
"Targeting of Drugs: Strategies for Stealth Therapeutic Systems,"
held in Cape Sounion during 24 June -5 July 1997. As the title
implies, the book deals with a variety of approaches to evade the
reticuloendothelial system and thus extend the circulation time of
a variety of delivery systems including polymers, biopolymers,
liposomes, and other nanoparticles or microparticles. We express
our appreciation to Mrs. Concha Perring for her assistance with the
organization of the AS . The ASI was held under the sponsorship of
NATO Scientific Affairs Division and supported by Sequus
Pharmaceuticals (Menlo Park, CA, USA), The Liposome Company
(Princeton, NJ, USA), NOVO Nordisk (Bagsvaard, Denmark), NeXstar
Pharmaceuticals (Boulder, CO, USA), Gene Medicine (Houston, TX,
USA), Pfizer Ltd (Sandwich, Kent, UK), Merck (Rahway, NJ, USA), and
Biovation Ltd (Aberdeen, UK).
The NATO Advanced Studies Institute series "Targeting of Drugs" was
originated in 1981. It is now a major international forum, held
every two years in Cape Sounion, Greece, in which the present and
the future of this important area of research in drug delivery is
discussed in great depth. Previous ASIs of the series dealt with
drug carriers of natural and synthetic origin, their interaction
with the biological milieu, ways by which the latter influences
such interaction, strategies by which milieu interference
curtailing the function of drug carriers is circumvented and, more
recently, with the application of drug carriers for the delivery of
peptides and proteins. The present book contains the of the 7th
NATO ASI "Targeting of Drugs: Advances in System Constructs,"
proceedings held in Cape Sounion during 24 June -5 July 1993. As
the title implies, the book deals with a variety of approaches to
carrier design or modification that contribute to optimal carrier
function. to Mrs Concha Perring for her assistance with the We
express our appreciation organization of the ASI. We thank Dr. G.
Deliconstantinos who, as chairperson of the Local Committee,
contributed to the success of the Institute. The ASI was held under
the sponsorship of NATO Scientific Affairs Division and
co-sponsored and generously financed by SmithKline Beecham
Pharmaceuticals (King of Prussia). Financial assistance was also
provided by Liposome Technology Inc. (Menlo Park), Vestar Inc. (San
Dimas) and Zeneka (Macclesfield).
TheNATO
AdvancedStudiesInstituteseries"TargetingofDrugs"wasoriginatedin
1981. It is nowamajorinternationalforum,heldeverytwo yearsin
CapeSounion,Greece,in
whichthepresentandthefutureofthisimportantareaofresearch in
drugdeliveryisdiscussed in greatdepth.
PreviousASIsoftheseriesdealtwith drugcarriersofnaturalandsynthetic
origin,theirinteractionswith thebiologicalmilieu, waysby
whichthefunctionofdrugcarriers iscircumvented and,morerecently,with
avarietyofapproaches to carrierdesignor
modificationthatcontributeto optimalcarrierfunction.
Thepresentbookcontainsthe proceedings ofthe8thNATO ASI,
"TargetingofDrugs:Strategies for Oligonucleotideand GeneDelivery in
Therapy", held in CapeSounionduring24June-5 July 1995. Asthetitle
implies,thebookdealswith avarietyofsystemsin termsoftheirability to
transportnucleic acidsto targetareasin vitro andin vivo in
waysthateffectivelymodify,supplement, correct,
orcurtailthefunctionofgenesin therapy. Weexpressourappreciation to
Mrs. ConchaPerringfor herassistance with the organizationoftheASI.
TheASI washeldunderthesponsorship ofNATO ScientificAffairs Division
andco-sponsored andgenerouslyfinancedby
SmithKlineBeechamPharmaceuticals (KingofPrussia).
Financialassistance wasalsoprovidedby SandozPharma(Baseland
Athens),GeneMedicine (Houston,USA),
ChironCorporation(Emeryville,USA), BYK GuldenLombergChemische
(Konstanz,Gernlany),HelpSA(Athens,Greece),Avanti Polar Lipids Inc
(Birmingham,USA), OxfordMolecular(Oxford,UK), Pfizer(Kent,UK),
andAlza Corporation(PaloAlto, USA). GregoryGregoriadis
BrendaMcCormack v CONTENTS Gene Therapy for Inherited Genetic
Disease: Possibilities and Problems c. *Coutelle Gene Delivery and
Therapy: The Case for Cystic Fibrosis 15 E. W. F. W. Alton Immune
Responses with Direct Gene Transfer: DNA Vaccines and 21
Implications for Gene Therapy H. L. Davis Oligonucleotides:
Molecular Versions for Optimal Use in Vivo 31 E. Saison-Behmoaras,
A. Van Aerschot, I. Duroux, C. Hendrix, C. Helene, and P. Herdewijn
Retrovirus Vectors in Gene Therapy: Targeting to Specific Cells 45
AJ. Kingsman, Y. Bae, J. c. Griffiths, N. Kim, E. E. Ramsdale, G.
Romano, Y. Soneoka, P. M. Cannon, and S. M. Kingsman Adenovirus as
Vectors for Gene Therapy 53 M. G. Lee Receptor-Mediated Gene
Delivery with Synthetic Virus-like Particles 67 E. Wagner, M.
Cotten, and K. Zatloukal Controllable Gene Therapy: Recent Advances
in Non-Viral Gene Delivery 79 A.
It is widely accepted that vaccination still renains the best
answer to ITDst infectious diseases. Recently, vaccine developnent
has been greatly facilitated by advances in ITDlecular and cell
biology which have laid the foundations of a new generation of
vaccines. '!hese are exemplified by submit vaccines produced
through gene cloning and synthetic peptides mimicking snall regions
of proteins on the outer coat of viruses and capable of eliciting
virus neutralizing antibodies. However, submit and peptide vaccines
are only weakly or non-inmmogenic in the absence of immunological
adjuvants. The latter are a diverse array of agents that augment
specific cell-mediated immune responses to the antigens and the
formation of protective antibodies. '!his book contains the
proceedings of the 3rd NATO Advanced Studies Institute (ASI)
"New-Generation vaccines: '!he Role of Basic Irrmmology" held at
Cape Sounion Beach, Greece, during 24 June-5 July, 1992. It deals
with recent developnents in the understanding of inmmity at the
ITDlecular and cellular levels and the application of such
knowledge in the search for novel inmmological adjuvants and the
fonnulation of new-generation vaccines for experimental and
clinical use. We express our appreciation to Professor K. Dalsgaard
and H. Snippe for their cooperation in planning the ASI and to Mrs.
Concha Perring for her excellent production of the manu- scripts.
'!he ASI was held tmder the sponsorship of NATO Scientific Affairs
Division and generously co-sponsored by SrnithKline Beecham
Pharmaceuticals (Fhiladelp,. ia). Financial assistance was also
provided by Pasteur Merieux (Marcy L'Etoile), British Biotechnology
Ltd.
During the last decade or so vaccine development has been
facilitated by rapid advances in molecular and cell biology. These
have laid the foundations of a new generation of vaccines
exemplified by subunit vaccines produced through gene cloning and
by synthetic peptides mimicking small regions of proteins on the
outer coat of viruses. Such peptide~ are capable of eliciting
virus-neutralizing antibodies. Unfortunately, subunit and peptide
vaccines are only weakly or non immunogenic in the absence of
immunological adjuvants that are known to augment specific
cell-mediated immune responses to the antigens and to promote the
formation of protective antibodies. This book contains the
proceedings of the 4th NATO Advanced Studies Institute (ASI)
"Vaccines: New Generation Immunological Adjuvants" held at Cape
Sounion Beach, Greece, during 24 June -5 . July 1994 and deals in
depth with both theoretical and practical aspects of vaccinology.
These include the role of antigen presenting cells in the induction
of immune responses. immunopotentiation by a variety of new
generation immunological adjuvants and vaccine carriers. and recent
advances and perspectives in experimental vaccines as well as
vaccinatioll with nucleic acids. We express our appreciation to Dr.
K. Dalsgaard and Dr. J. L. Virelizier for their cooperatioll in
planning the ASI and to Mrs. Concha Pening for her excellent
production of the manuscripts. The ASI was held under the
sponsorship of NATO Scientific Affairs Division and generously
co-sponsored by SmithKline Beecham Pharmaceuticals (Philadelphia).
The NATO Advanced Studies Institute series "Targeting of Drugs" was
originated in 1981. It is now a major international forum, held
every two years in Cape Sounion, Greece, in which the present and
the future of this important area of research in drug delivery is
discussed in great depth. Previous ASIs of the series dealt with
drug carriers of natural and synthetic origin, their interactions
with the biological milieu, ways by which milieu interference is
circumvented, approaches to carrier design or modification that
contribute to optimal carrier function, and, more recently, with
strategies for gene and oligonucleotide delivery in therapy The
present book contains the proceedings of the 9th NATO ASI,
"Targeting of Drugs: Strategies for Stealth Therapeutic Systems,"
held in Cape Sounion during 24 June -5 July 1997. As the title
implies, the book deals with a variety of approaches to evade the
reticuloendothelial system and thus extend the circulation time of
a variety of delivery systems including polymers, biopolymers,
liposomes, and other nanoparticles or microparticles. We express
our appreciation to Mrs. Concha Perring for her assistance with the
organization of the AS . The ASI was held under the sponsorship of
NATO Scientific Affairs Division and supported by Sequus
Pharmaceuticals (Menlo Park, CA, USA), The Liposome Company
(Princeton, NJ, USA), NOVO Nordisk (Bagsvaard, Denmark), NeXstar
Pharmaceuticals (Boulder, CO, USA), Gene Medicine (Houston, TX,
USA), Pfizer Ltd (Sandwich, Kent, UK), Merck (Rahway, NJ, USA), and
Biovation Ltd (Aberdeen, UK).
During the last decade or so vaccine development has been
facilitated by rapid ad- vances in the molecular and cell biology
ofthe immune system. This has laid the foundations of a new
generation of vaccines exemplified by subunit vaccines produced
through gene cloning and by synthetic peptides mimicking small
regions ofproteins on the outer coat ofvi- ruses. However, as
subunit and peptide vaccines are only weakly or non-immunogenic,
there is areal need for strategies to improve their potency. This
book contains the proceedings of the 5th NATO Advanced Studies
Institute (ASI), "Vaccine Design: The Role of Cytokine Networks,"
held at Cape Sounion Beach, Greece, during 24 June-5 July 1996 and
deals in depth with the role ofbasic immunology in the regulation
of immunity and vaccine design. Special emphasis is given to the
use of cyto- kines in conjuction with vaccines with the aim
ofimproving their potency or the use ofvac- cines designed to
improve cytokine production. We express our appreciation to Dr.
J.-L. Virelizier and Dr. G. Kollias for their cooperation in
planning the ASI and to Mrs. Concha Perring for her excellent
production ofthe manuscripts. The ASI was held under the sponsor-
ship of NATO Scientific Affairs Division and generously
co-sponsored by SmithKline Beecham Pharmaceuticals (Philadelphia).
Financial assistance was also provided by Connaught Laboratories
Ltd. (Ontario), Pasteur Merieux (Marcy I 'Etoile), Biochine
(Siena), Help SA (Athens), and Avanti Polar Lipids Inc.
(Birmingham, USA).
The 19 papers explore a variety of systems in terms of their
ability to transport nucleic acids to target areas in vitro and in
vivo in ways that effectively modify, supplement, correct, or
curtail the function of genes in therapy. Among the topics are
cystic fibrosis, immune responses with direct g
During the last decade or so vaccine development has been
facilitated by rapid advances in molecular and cell biology. These
have laid the foundations of a new generation of vaccines
exemplified by subunit vaccines produced through gene cloning and
by synthetic peptides mimicking small regions of proteins on the
outer coat of viruses. Such peptide~ are capable of eliciting
virus-neutralizing antibodies. Unfortunately, subunit and peptide
vaccines are only weakly or non immunogenic in the absence of
immunological adjuvants that are known to augment specific
cell-mediated immune responses to the antigens and to promote the
formation of protective antibodies. This book contains the
proceedings of the 4th NATO Advanced Studies Institute (ASI)
"Vaccines: New Generation Immunological Adjuvants" held at Cape
Sounion Beach, Greece, during 24 June -5 . July 1994 and deals in
depth with both theoretical and practical aspects of vaccinology.
These include the role of antigen presenting cells in the induction
of immune responses. immunopotentiation by a variety of new
generation immunological adjuvants and vaccine carriers. and recent
advances and perspectives in experimental vaccines as well as
vaccinatioll with nucleic acids. We express our appreciation to Dr.
K. Dalsgaard and Dr. J. L. Virelizier for their cooperatioll in
planning the ASI and to Mrs. Concha Pening for her excellent
production of the manuscripts. The ASI was held under the
sponsorship of NATO Scientific Affairs Division and generously
co-sponsored by SmithKline Beecham Pharmaceuticals (Philadelphia).
The NATO Advanced Studies Institute series "Targeting of Drugs" was
originated in 1981. It is now a major international forum, held
every two years in Cape Sounion, Greece, in which the present and
the future of this important area of research in drug delivery is
discussed in great depth. Previous ASIs of the series dealt with
drug carriers of natural and synthetic origin, their interaction
with the biological milieu, ways by which the latter influences
such interaction, strategies by which milieu interference
curtailing the function of drug carriers is circumvented and, more
recently, with the application of drug carriers for the delivery of
peptides and proteins. The present book contains the of the 7th
NATO ASI "Targeting of Drugs: Advances in System Constructs,"
proceedings held in Cape Sounion during 24 June -5 July 1993. As
the title implies, the book deals with a variety of approaches to
carrier design or modification that contribute to optimal carrier
function. to Mrs Concha Perring for her assistance with the We
express our appreciation organization of the ASI. We thank Dr. G.
Deliconstantinos who, as chairperson of the Local Committee,
contributed to the success of the Institute. The ASI was held under
the sponsorship of NATO Scientific Affairs Division and
co-sponsored and generously financed by SmithKline Beecham
Pharmaceuticals (King of Prussia). Financial assistance was also
provided by Liposome Technology Inc. (Menlo Park), Vestar Inc. (San
Dimas) and Zeneka (Macclesfield).
During the last decade or so vaccine development has been
facilitated by rapid ad- vances in the molecular and cell biology
ofthe immune system. This has laid the foundations of a new
generation of vaccines exemplified by subunit vaccines produced
through gene cloning and by synthetic peptides mimicking small
regions ofproteins on the outer coat ofvi- ruses. However, as
subunit and peptide vaccines are only weakly or non-immunogenic,
there is areal need for strategies to improve their potency. This
book contains the proceedings of the 5th NATO Advanced Studies
Institute (ASI), "Vaccine Design: The Role of Cytokine Networks,"
held at Cape Sounion Beach, Greece, during 24 June-5 July 1996 and
deals in depth with the role ofbasic immunology in the regulation
of immunity and vaccine design. Special emphasis is given to the
use of cyto- kines in conjuction with vaccines with the aim
ofimproving their potency or the use ofvac- cines designed to
improve cytokine production. We express our appreciation to Dr.
J.-L. Virelizier and Dr. G. Kollias for their cooperation in
planning the ASI and to Mrs. Concha Perring for her excellent
production ofthe manuscripts. The ASI was held under the sponsor-
ship of NATO Scientific Affairs Division and generously
co-sponsored by SmithKline Beecham Pharmaceuticals (Philadelphia).
Financial assistance was also provided by Connaught Laboratories
Ltd. (Ontario), Pasteur Merieux (Marcy I 'Etoile), Biochine
(Siena), Help SA (Athens), and Avanti Polar Lipids Inc.
(Birmingham, USA).
|
You may like...
Gloria
Sam Smith
CD
R407
Discovery Miles 4 070
|